Can a Moisturizer Change the Eczema Microbiome? A 7-Day Study With 22 Analyzed
Dr. Arsy Editorial Team · November 9, 2026
A skin microbiome measurement is not the same as an eczema treatment result. A short experiment enrolled 15 adults with atopic dermatitis and 15 healthy controls; microbiome profiling was completed for 13 and nine respectively. After seven days, the tested moisturizer and fragrance compound did not produce significant overall changes in the main microbiome comparisons. [9]
Four areas, not four independent patient groups
Researchers assigned four predefined areas of each participant's skin to no treatment, a moisturizer, farnesol, or moisturizer plus farnesol. Participants applied the assigned preparations for seven days. Because several areas belonged to the same person, the number of treated areas must not be presented as the number of independent participants. The moisturizer was a particular commercial gel; it was not Dr. Arsy #003. [9]
The people with eczema had different microbial profiles from the healthy controls at baseline. That observation shows an association in this selected sample; it does not prove that a particular bacterium caused every participant's eczema or that a simple product change can reverse it. [9][11][12]
What did and did not change?
| Outcome | Reading the result |
|---|---|
| Microbial richness and overall composition | No significant overall shift was found after the short interventions in either cohort. |
| Shannon diversity | A modest within-group change was reported in moisturizer-treated healthy controls; it was not a demonstrated clinical benefit in the eczema group. |
| Local skin score | A small improvement from baseline was reported on moisturizer-treated eczema skin; a within-area change is not by itself proof of superiority over untreated skin. |
Twenty-two people contributed the microbiome profiling, the eczema population was relatively small and largely mildly affected, and the intervention lasted only a week. The study cannot establish what would happen over months or with a different cream. [9]
Does farnesol belong in an eczema routine?
The fact that a fragrance compound was investigated in a study is not a recommendation to add it to sensitive skin. Tolerability and contact allergy differ between people, concentrations and formulas. If a moisturizer or fragranced product causes a recurrent rash or stinging, stop it and ask a clinician whether irritation or contact allergy needs investigation. [9][19][20]
Why this result is useful
Microbiome studies use different techniques and endpoints. In trials of investigational enzymes, researchers measured bacterial cultures and clinical scores; work on live bacterial approaches and bacterial lysates used other comparisons. A small change in a laboratory index does not automatically mean less itch, fewer flares or a healthier result for every person. [1][2][3][4][5][6][7][8][10]
Other work has examined topical antimicrobials, systemic therapies, pediatric formulations and barrier measures. These studies can generate useful questions, but the results belong to the actual products and populations tested. [14][15][16][17][18]
Read the wider evidence in context
Skin-microbiome research includes studies of live organisms, inactive bacterial material, proteins targeting bacteria, and ordinary skin-care products. Clinical scores, itch reports, skin barrier tests and bacterial measures do not answer the same question. Guidelines support individualized eczema care and moisturization; studies of other formulas cannot be transferred to a different product. [11][12][13][14][15][16][17][18][19][20]
Dr. Arsy #003 in a daily routine
Explore Dr. Arsy™ Hydration Recovery Moisturizer #003, 4 oz, a fragrance-free moisturizer for dry, sensitive and eczema-prone skin. The studies discussed here did not test #003 and do not show that it alters the microbiome, treats eczema or treats infection. For babies, ask the child's clinician before choosing skin-care products.
Related reading
- Endolysin XZ.700 for Eczema: What a 39-Person Study Actually Found
- B244 for Eczema Itch: What the 547-Adult Trial Measured
- Staphylococcus hominis A9 and Eczema: Why a Safety Trial Was Not Proof of Clearance
- A Nature-Derived Microbial Lotion for Eczema: Why a 28-Day Signal Needs a Placebo
- Microbiome treatments: why later trials matter
- Eczema or skin infection? Warning signs and care
Research and clinical references
- XZ.700: first-in-human randomized endolysin study.
- SA.100: vehicle-controlled endolysin trial.
- B244: phase 2b ammonia-oxidizing bacteria trial.
- Staphylococcus hominis A9 phase 1 clinical trial.
- FB-401: placebo-controlled Roseomonas trial.
- First-in-human Roseomonas mucosa research.
- Roseomonas mucosa research in children.
- Lactobacillus lactis lysate: placebo-controlled pilot.
- Moisturizer and farnesol: skin-microbiome experiment.
- Inactivated environmental microbial extract: pilot trial.
- Staphylococcus aureus and eczema severity: systematic review.
- International Eczema Council: skin bacteria and infection.
- Infectious complications of atopic dermatitis.
- Topical niclosamide and the eczema skin microbiome.
- Isosorbide diesters and the pediatric skin microbiome.
- Antimicrobial-corticosteroid combinations and skin microbiome.
- Systemic eczema therapies and skin bacteria: pilot research.
- Emollients and skin-barrier function: systematic review.
- AAD guideline: pediatric eczema management.
- AAD guideline: adult eczema topical management.
Educational information; not a diagnosis or individual medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.